Differences between opioids: pharmacological, experimental, clinical and economical perspectives

Abstract

Clinical studies comparing the response and side effects of various opioids have not been able to show robust differences between drugs. Hence, recommendations of the regulatory authorities have been driven by costs with a general tendency in many countries to restrict physician's use of opioids to morphine. Although this approach is recognized as cost-effective in most cases there is solid evidence that, on an individual patient basis, opioids are not all equal. Therefore it is important to have an armamentarium of strong analgesics in clinical practice to ensure a personalized approach in patients who do not respond to standard treatment. In this review we highlight differences between opioids in human studies from a pharmacological, experimental, clinical and health economics point of view. We provide evidence that individuals respond differently to opioids, and that general differences between classes of opioids exist. We recommend that this recognition is used to individualize treatment in difficult cases allowing physicians to have a wide range of treatment options. In the end this will reduce pain and side effects, leading to improved quality of life for the patient and reduce the exploding pain related costs.

The genetic influences on oxycodone response characteristics in human experimental pain

“…The mu‐opioid receptor is the primary target for opioid analgesics, and therefore, it is not surprising that OPRM1 SNPs show the strongest effect. Individuals often respond differently to different opioids . This study has focussed on oxycodone; thus, findings may not be applicable to other opioids.…”

Acute Metabolic Changes Associated With Analgesic Drugs: An MR Spectroscopy Study

“…Opioids and antidepressives are often used in treatment of chronic pain, but the analgesic effect is very individual with some people not responding adequately to treatment and often with unpredictable side effects. 8 Therefore, MRS with measurement of metabolites may provide further insight into drug treatment mechanisms and has the potential as a biomarker to predict treatment outcomes and side effects. 9 We conducted this explorative study with the aim to investigate the central effects of analgesic drugs in healthy subjects.…”

Physician-Delivered Injection Therapies for Mechanical Neck Disorders: A Systematic Review Update (Non-Oral, Non-Intravenous Pharmacological Interventions for Neck Pain)

“…However a 2012 study suggests steroids may have more of an effect in reducing pain than inflammation [12]. …”